MOTS-c and Exercise: Human Measurements vs Mouse Evidence

The key distinction

Two facts are often cited together and are not the same fact. First: in people, exercise can be associated with changes in endogenous MOTS-c that circulates or is measured in muscle. Second: in mice, MOTS-c has been administered and physical-capacity outcomes have been studied.^2,1

The first is a physiological measurement. The second is a preclinical intervention. Mixing them produces the marketing phrase “exercise in a bottle.” This page does not use that phrase as a thesis. The general map is in the MOTS-c hub.

What exercise measures in people

Participants in the human exercise studies exercised. They were not given investigational MOTS-c as a therapeutic intervention. The object of measurement was the peptide the body already makes, sometimes together with other mitochondrial-derived peptides such as humanin.²

A biomarker change after training can be interesting for exercise physiology. It does not answer the question “what happens if the peptide is given to a person.”

Human measurements

Reynolds and colleagues (2021) include human exercise-related observations as well as mouse experiments. The human part of that paper is read as measurement and as aging or muscle context. It is not read as a treatment trial.¹

When a popular summary says that “exercise induces MOTS-c,” the careful reading is: exercise was associated with changes in endogenous MOTS-c. The word induces does not authorize selling the peptide as a substitute for training.

• Human model: exercise, blood, sometimes muscle.^2,1
• Human intervention in those papers: exercise, not the peptide.²
• Result that can be stated: an endogenous change was measured.²
• Result that cannot be stated: administered peptide improves human performance.

Administration in mice

A physical-capacity outcome in a mouse is not a human treatment trial. It is not presented here as proof that people perform better, recover more, or age less if they receive MOTS-c.¹

The 2015 discovery work had already placed skeletal muscle at the center of the preclinical metabolic narrative. Reynolds extends that line toward exercise and aging in models. The extension remains, on the administration side, preclinical.^3,1

How to read Reynolds 2021

The Nature Communications paper is a mixed object. It contains mouse work and human observation. A reader who cites only the title — “exercise-induced” — can erase that mix. Here it stays visible.¹

“Exercise-induced” in the title refers to MOTS-c as an exercise-linked regulator in the paper’s frame. It does not turn mouse administration into a clinical trial, and it does not turn human measurement into human administration.

Why we do not say “exercise mimetic”

“Exercise mimetic” and “exercise in a bottle” are marketing terminology. They can appear in commercial copy that collapses endogenous measurement with preclinical administration. This page mentions them only to reject them as an established scientific classification.

A mimetic, strictly speaking, would imply that the peptide reproduces the effects of exercise in people. That claim is not supported by a human administration trial with posted results. NCT07505745 studies insulin sensitivity, not an “exercise-equivalence” endpoint.⁴

Translation limits

Translation asks for a bridge that is not yet published: controlled administration in people, with measured endpoints and results in view. Until then, human exercise informs endogenous physiology and the mouse informs preclinical intervention.^2,1

What this literature does not prove

• It does not prove that MOTS-c is exercise in a bottle.
• It does not prove a performance benefit in athletes or in the general public.
• It does not prove that administering the peptide reproduces training.
• It does not replace the human inventory or the Phase 2a trial.⁴

The human inventory is in MOTS-c in humans. Muscle mechanism is discussed in proposed mechanisms.